News

  • 5 December 2017

    La Jolla begins clinical trial of LJPC-401 for beta-thalassemia

    La Jolla Pharmaceutical Company has started a pivotal clinical study of synthetic human hepcidin (LJPC-401) to treat patients with transfusion-dependent beta-thalassemia who have cardiac iron levels above normal, despite chelation...